Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions

References

• PietrangeloAPhysiology of iron transport and the hemochromatosis geneAm J Physiol Gastrointest Liver Physiol20022823G403G41411841990
   PubMed Web of Science ®Google Scholar
• KnutsonMWessling-ResnickMIron metabolism in the reticuloendothelial systemCrit Rev Biochem Mol Biol2003381618812641343
   PubMed Web of Science ®Google Scholar
• HoffbrandAVTaherACappelliniMDHow I treat transfusional iron overloadBlood2012120183657366922919029
   PubMed Web of Science ®Google Scholar
• FilletGBeguinYBaldelliLModel of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammationBlood19897428448512502204
   PubMed Web of Science ®Google Scholar
• BreuerWHershkoCCabantchikZIThe importance of non-transferrin bound iron in disorders of iron metabolismTransfus Sci200023318519211099894
   PubMedGoogle Scholar
• NemethETuttleMSPowelsonJHepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalizationScience200430657042090209315514116
   PubMed Web of Science ®Google Scholar
• NemethEIron regulation and erythropoiesisCurr Opin Hematol200815316917518391780
   PubMed Web of Science ®Google Scholar
• TannoTPorayettePSripichaiOIdentification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cellsBlood2009114118118619414861
   PubMed Web of Science ®Google Scholar
• TannoTBhanuNVOnealPAHigh levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidinNat Med20071391096110117721544
   PubMed Web of Science ®Google Scholar
• TannoTRabelALeeYTYauYYLeitmanSFMillerJLExpression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donationTransfusion20105071532153520210929
   PubMed Web of Science ®Google Scholar
• CasanovasGVujić SpasicMCasuCThe murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized miceHaematologica201398344444722983584
   PubMed Web of Science ®Google Scholar
• KautzLJungGValoreEVRivellaSNemethEGanzTIdentification of erythroferrone as an erythroid regulator of iron metabolismNat Genet201446767868424880340
   PubMed Web of Science ®Google Scholar
• NovartisDesferal (Deferoxamine Mesylate) Prescribing InformationSwitzerlandNovartis Pharmaceuticals2011
   Google Scholar
• PorterJBAbeysingheRDMarshallLHiderRCSinghSKinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapyBlood19968827057138695819
   PubMed Web of Science ®Google Scholar
• BarryMFlynnDMLetskyEARisdonRALong-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progressBr Med J19742590916204821036
   PubMed Web of Science ®Google Scholar
• ModellBLetskyEAFlynnDMPetoRWeatherallDJSurvival and desferrioxamine in thalassaemia majorBr Med J19822846322108110846802413
   PubMed Web of Science ®Google Scholar
• Borgna-PignattiCRugolottoSDe StefanoPSurvival and complications in patients with thalassemia major treated with transfusion and deferoxamineHaematologica200489101187119315477202
   PubMed Web of Science ®Google Scholar
• BrittenhamGMGriffithPMNienhuisAWEfficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia majorN Engl J Med199433195675738047080
   PubMed Web of Science ®Google Scholar
• AndersonLJWestwoodMAHoldenSMyocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBr J Haematol2004127334835515491298
   PubMed Web of Science ®Google Scholar
• DavisBAPorterJBLong-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemiaBlood20009541229123610666195
   PubMed Web of Science ®Google Scholar
• CohenAMartinMMizaninJKonkleDFSchwartzEVision and hearing during deferoxamine therapyJ Pediatr19901172 pt 13263302380834
   PubMed Web of Science ®Google Scholar
• OlivieriNFBuncicJRChewEVisual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusionsN Engl J Med1986314148698733485251
   PubMed Web of Science ®Google Scholar
• CohenARGalanelloRPennellDJCunninghamMJVichinskyEThalassemiaHematology Am Soc Hematol Educ Program20041143415561674
   PubMedGoogle Scholar
• DeleaTEEdelsbergJSofryginOConsequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature reviewTransfusion200747101919192917880620
   PubMed Web of Science ®Google Scholar
• AgencyEMFerriprox: EPAR – Product Information2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000236/WC500022050.pdf2014
   Google Scholar
• TraynorKDeferiprone approved for iron overloadAm J Health Syst Pharm201168222106
   Web of Science ®Google Scholar
• Borgna-PignattiCCappelliniMDDe StefanoPCardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia majorBlood200610793733373716373663
   PubMed Web of Science ®Google Scholar
• PigaAGagliotiCFogliaccoETrictaFComparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysisHaematologica200388548949612745268
   PubMed Web of Science ®Google Scholar
• AddisALoebsteinRKorenGEinarsonTRMeta-analytic review of the clinical effectiveness of oral deferiprone (L1)Eur J Clin Pharmacol19995511610206077
   PubMed Web of Science ®Google Scholar
• MaggioAD’AmicoGMorabitoADeferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trialBlood Cells Mol Dis200228219620812064916
   PubMed Web of Science ®Google Scholar
• TaherASheikh-TahaMShararaASafety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year studyActa Haematol2005114314614916227677
   PubMed Web of Science ®Google Scholar
• AndersonLJWonkeBPrescottEHoldenSWalkerJMPennellDJComparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemiaLancet2002360933251652012241655
   PubMed Web of Science ®Google Scholar
• PennellDJBerdoukasVKaragiorgaMRandomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood200610793738374416352815
   PubMed Web of Science ®Google Scholar
• BerdoukasVChouliarasGMoraitisPZannikosKBerdoussiELadisVThe efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational studyJ Cardiov Magn Reson20091120
   PubMed Web of Science ®Google Scholar
• PennellDJCarpenterJPRoughtonMCabantchikZOn improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failureJ Cardiov Magn Reson20111345
   PubMed Web of Science ®Google Scholar
• MaggioAVitranoACapraMImproving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and HemoglobinopathiesBlood Cells Mol Dis200942324725119233692
   PubMed Web of Science ®Google Scholar
• CohenARGalanelloRPigaADe SanctisVTrictaFSafety and effectiveness of long-term therapy with the oral iron chelator deferiproneBlood200310251583158712763939
   PubMed Web of Science ®Google Scholar
• OlivieriNFBrittenhamGMMcLarenCELong-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia majorN Engl J Med199833974174239700174
   PubMed Web of Science ®Google Scholar
• WuSFPengCTWuKHTsaiCHLiver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patientsHemoglobin200630221521816798646
   PubMed Web of Science ®Google Scholar
• WanlessIRSweeneyGDhillonAPLack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemiaBlood200210051566156912176871
   PubMed Web of Science ®Google Scholar
• TaherAAounEShararaAIFive-year trial of deferiprone chelation therapy in thalassaemia major patientsActa Haematol2004112417918315564727
   PubMed Web of Science ®Google Scholar
• Exjade (deferasirox)prescribing informationSwitzerlandNovartis Pharmaceuticals2005
   Google Scholar
• GoldbergSLGiardinaPJChirnomasDEspositoJPaleyCVichinskyEThe palatability and tolerability of deferasirox taken with different beverages or foodsPediatr Blood Cancer20136091507151223637051
   PubMed Web of Science ®Google Scholar
• SéchaudRDutreixCBalezSRelative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinksInt J Clin Pharmacol Ther200846210210818218291
   PubMed Web of Science ®Google Scholar
• PigaAGalanelloRForniGLRandomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadHaematologica200691787388016818273
   PubMed Web of Science ®Google Scholar
• GalanelloRPigaAForniGLPhase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia majorHaematologica200691101343135117018383
   PubMed Web of Science ®Google Scholar
• CappelliniMDCohenAPigaAA phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaBlood200610793455346216352812
   PubMed Web of Science ®Google Scholar
• PorterJGalanelloRSaglioGRelative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective studyEur J Haematol200880216817618028431
   PubMed Web of Science ®Google Scholar
• TaherAEl-BeshlawyAElalfyMSEfficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR studyEur J Haematol200982645846519187278
   PubMed Web of Science ®Google Scholar
• TaherACappelliniMDVichinskyEEfficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overloadBr J Haematol2009147575275919764988
   PubMed Web of Science ®Google Scholar
• DeugnierYTurlinBRopertMImprovement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 yearsGastroenterology20111414120212111211. e1201120321741344
   PubMed Web of Science ®Google Scholar
• CappelliniMDPorterJEl-BeshlawyAEPIC Study InvestigatorsTailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasHaematologica201095455756619951979
   PubMed Web of Science ®Google Scholar
• PorterJBElalfyMSTaherATEfficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudyAnn Hematol201392221121923086508
   PubMed Web of Science ®Google Scholar
• PennellDJPorterJBCappelliniMDDeferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia majorHaematologica201297684284822271905
   PubMed Web of Science ®Google Scholar
• PennellDJPorterJBPigaACORDELIA study investigatorsA 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)Blood2014123101447145424385534
   PubMed Web of Science ®Google Scholar
• WonkeBWrightCHoffbrandAVCombined therapy with deferiprone and desferrioxamineBr J Haematol199810323613649827905
   PubMed Web of Science ®Google Scholar
• BreuerWErmersMJPootrakulPAbramovAHershkoCCabantchikZIDesferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapyBlood200197379279811157499
   PubMed Web of Science ®Google Scholar
• LinkGKonijnAMBreuerWCabantchikZIHershkoCExploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in cultureJ Lab Clin Med2001138213013811477380
   PubMed Web of Science ®Google Scholar
• EvansPKayyaliRHiderRCEcclestonJPorterJBMechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiproneTrans Res201015625567
   Web of Science ®Google Scholar
• PennellDJUdelsonJEAraiAEAmerican Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and ImagingCardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart AssociationCirculation2013128328130823775258
   PubMed Web of Science ®Google Scholar
• MouradFHHoffbrandAVSheikh-TahaMKoussaSKhoriatyAITaherAComparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patientsBr J Haematol2003121118718912670352
   PubMed Web of Science ®Google Scholar
• GomberSSaxenaRMadanNComparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic childrenIndian Pediatr2004411212714767084
   PubMedGoogle Scholar
• HaSYChikKWLingSCA randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong KongHemoglobin200630226327416798652
   PubMed Web of Science ®Google Scholar
• AydinokYUlgerZNartDA randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia majorHaematologica200792121599160618055982
   PubMed Web of Science ®Google Scholar
• El-BeshlawyAManzCNajaMIron chelation in thalassemia: combined or monotherapy? The Egyptian experienceAnn Hematol200887754555018351337
   PubMed Web of Science ®Google Scholar
• LaiMEGradyRWVacquerSIncreased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to deferoxamine aloneBlood Cells Mol Dis201045213613920678715
   PubMed Web of Science ®Google Scholar
• LadisVChouliarasGBerdoukasVRelation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek UnitEur J Haematol201085433534420561034
   PubMed Web of Science ®Google Scholar
• TelferPTWarburtonFChristouSImproved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiproneHaematologica200994121777177819815834
   PubMed Web of Science ®Google Scholar
• TannerMAGalanelloRDessiCA randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonanceCirculation2007115141876188417372174
   PubMed Web of Science ®Google Scholar
• TannerMAGalanelloRDessiCCombined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJ Cardiov Magn Reson20081012
   PubMed Web of Science ®Google Scholar
• FarmakiKTzoumariIPappaCChouliarasGBerdoukasVNormalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia majorBr J Haematol2010148346647519912219
   PubMed Web of Science ®Google Scholar
• KwiatkowskiJLReal-world use of iron chelatorsHematology Am Soc Hematol Educ Program2011201145145822160073
   PubMed Web of Science ®Google Scholar
• GalanelloRKattamisAPigaAA prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemiaHaematologica20069191241124316956824
   PubMed Web of Science ®Google Scholar
• AbdelrazikNPattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children’s Hospital experienceHematology200712657758517852442
   PubMed Web of Science ®Google Scholar
• MaggioAVitranoACapraMLong-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trialBr J Haematol2009145224525419236376
   PubMed Web of Science ®Google Scholar
• MaggioAFilosaAVitranoAIron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trialsBlood Cells Mol Dis201147316617521843958
   PubMed Web of Science ®Google Scholar
• FisherSABrunskillSJDoreeCGoodingSChowdhuryORobertsDJDesferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemiaThe Cochrane Database of Syst Rev20138Cd004450
   PubMedGoogle Scholar
• Otto-DuesselMBrewerCGonzalezINickHWoodJCSafety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overloadActa Haematol2008120212312819018129
   PubMed Web of Science ®Google Scholar
• VoskaridouEKomninakaVKaravasATerposEAkianidisVChristoulasDCombination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with beta-thalassemia major and severe iron burdenTransfusion201454364664923834310
   PubMed Web of Science ®Google Scholar
• LalASweetersNHerzMSafety of combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia [Abstract]Blood20091142021
   Web of Science ®Google Scholar
• GradyRWGalanelloRRandolphREKleinertDADessiCGiardinaPJToward optimizing the use of deferasirox: potential benefits of combined use with deferoxamineHaematologica201398112913522875626
   PubMed Web of Science ®Google Scholar
• LalAPorterJSweetersNCombined chelation therapy with deferasirox and deferoxamine in thalassemiaBlood Cells Mol Dis20135029910423151373
   PubMed Web of Science ®Google Scholar
• CassinerioEOrofinoNRoghiACombination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patientsBlood Cells Mol Dis201453316416724846580
   PubMed Web of Science ®Google Scholar
• AydinokYKattamisACappelliniMDDeferasirox– deferoxamine combination therapy reduces cardiac iron with rapid liver iron Removal in patients with severe transfusional iron overload (HYPERION)55th ASH annual meetingDecember 8, 2013New Orleans, LA
   Google Scholar
• Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia2015 Available from: https://clinicaltrials.gov/ct2/show/NCT01709032?term=Deferiprone+AND+deferasirox&rank=12015
   Google Scholar
• Study of Efficacy, Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload2015 Available from: https://clinicaltrials.gov/ct2/show/NCT01511848?term=Deferiprone+AND+deferasirox&rank=3Accessed 2015
   Google Scholar
• Clinical Trial of Deferasirox Combination Treatment with Deferiprone in Thalassaemia Patients2015 Available from: https://clinicaltrials.gov/ct2/show/NCT02198508?term=Deferiprone+AND+deferasirox&rank=42015
   Google Scholar
• VoskaridouEChristoulasDTerposESuccessful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapiesBr J Haematol2011154565465621615376
   PubMed Web of Science ®Google Scholar
• BaloccoMCarraraPPintoVForniGLDaily alternating deferasirox and deferiprone therapy for “hard-to-chelate” beta-thalassemia major patientsAm J Hematol201085646046120513129
   PubMed Web of Science ®Google Scholar
• AngelucciEBarosiGCamaschellaCItalian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disordersHaematologica200893574175218413891
   PubMed Web of Science ®Google Scholar
• YardumianATelferPDarbyshirePStandards for the Clinical Care of Children and Adults with Thalassaemia in the UK2nd ed2008 Available from:http://www.hbpinfo.com/ukts-standards-2008.pdf2015
   Google Scholar
• VichinskyELevineLStandard-of-Care Clinical Practice Guidelines2012 Available from: http://thalassemia.com/treatment-guidelines-5.aspx#gsc.tab=02015
   Google Scholar
• SayaniFWarnerMWuJWong-RiegerDHumphreysKOdameIGuidelines for the Clinical Care of Patients with Thalassemia in CanadaNicosia, CyprusThalassaemia International Federation2009
   Google Scholar
• HoPJTayLLindemanRCatleyLBowdenDKAustralian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemiasIntern Med J201141751652421615659
   PubMed Web of Science ®Google Scholar
• MusallamKMAngastiniotisMEleftheriouAPorterJBCross-talk between available guidelines for the management of patients with beta-thalassemia majorActa Haematol20131302647323485589
   PubMed Web of Science ®Google Scholar
• CappelliniMDCohenAPorterJTaherAViprakasitVGuidelines for the Management of Transfusion Dependent Thalassemia3rd edNicosia, CyprusThalassaemia International Federation2014
   Google Scholar
• ModellBKhanMDarlisonMSurvival in beta-thalassaemia major in the UK: data from the UK Thalassaemia RegisterLancet200035592202051205210885361
   PubMed Web of Science ®Google Scholar
• Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet2015 Available from: https://clini-caltrials.gov/ct2/show/study/NCT02125877?term=Deferasirox&rank=302015
   Google Scholar
• Pilot Study of the Pharmacokinetic Profile of a Single Dose of Deferiprone Sustained-Release Formulation in Healthy Volunteers2015 Available from: https://clinicaltrials.gov/ct2/show/NCT02189941?term=deferiprone&rank=5Accessed 2015
   Google Scholar
• Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox^® in Patients With Sickle Cell Disease2015 Available from: https://clinicaltrials.gov/ct2/show/study/NCT01835496?term=deferiprone&rank=9Accessed Jan 2015
   Google Scholar
• BergeronRJWiegandJMcManisJSBhartiNSinghSDesign, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analoguesJ Med Chem200851133913392318533709
   PubMed Web of Science ®Google Scholar
• BergeronRJWiegandJBhartiNMcManisJSSinghSDesferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicityBiometals201124223925821103911
   PubMed Web of Science ®Google Scholar
• BergeronRJBhartiNWiegandJMcManisJSSinghSAbboudKAThe impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analoguesJ Med Chem20105372843285320232803
   PubMed Web of Science ®Google Scholar
• Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients with β-Thalassemia2015 Available from: https://clinicaltrials.gov/ct2/show/record/NCT02274233?term=sp+420&rank=1
   Google Scholar
• RienhoffHYJrViprakasitVTayLA phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overloadHaematologica201196452152521173101
   PubMed Web of Science ®Google Scholar
• SuraganiRNCawleySMLiRModified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemiaBlood2014123253864387224795345
   PubMed Web of Science ®Google Scholar
• DussiotMMacielTTFricotAAn activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemiaNat Med201420439840724658077
   PubMed Web of Science ®Google Scholar